Cognition Therapeutics, Inc. Financing Cash Flow
Cognition Therapeutics, Inc. (CGTX) reported Financing Cash Flow of $6.38 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-07
- Cognition Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $6.61M, a 778.99% increase year-over-year.
- Cognition Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$233.00K, a 117.98% decline year-over-year.
- Cognition Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $605.00K, a 94.68% decline year-over-year.
- Cognition Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $33.92M, a 10209.12% increase year-over-year.
- Cognition Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $36.57M, a 55.19% increase from fiscal 2024.
- Cognition Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $23.57M, a 421.23% increase from fiscal 2023.
- Cognition Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $4.52M, a 18.48% decline from fiscal 2022.
- Cognition Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $5.55M, a 89.58% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $6.38M 10-Q · filed 2026-08-07 | $6.98M derived: sum of 3 quarters · filed 2026-08-07 | $40.90M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$233.00K 10-Q · filed 2026-05-08 | $372.00K derived: sum of 2 quarters · filed 2026-05-08 | $34.29M derived: sum of 3 quarters · filed 2026-05-08 | $35.04M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $605.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $34.52M derived: sum of 2 quarters · filed 2026-03-26 | $35.27M derived: sum of 3 quarters · filed 2026-08-07 | $36.57M 10-K · filed 2026-03-26 |
| 2025-09-30 | $33.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $34.67M derived: sum of 2 quarters · filed 2026-08-07 | $35.97M 10-Q · filed 2025-11-06 | $47.35M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $752.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $2.05M 10-Q · filed 2026-08-07 | $13.43M derived: sum of 3 quarters · filed 2026-08-07 | $13.76M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $1.30M 10-Q · filed 2026-05-08 | $12.68M derived: sum of 2 quarters · filed 2026-05-08 | $13.01M derived: sum of 3 quarters · filed 2026-05-08 | $12.87M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $11.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $11.71M derived: sum of 2 quarters · filed 2026-03-26 | $11.57M derived: sum of 3 quarters · filed 2026-03-26 | $23.57M 10-K · filed 2026-03-26 |
| 2024-09-30 | $329.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $191.00K derived: sum of 2 quarters · filed 2025-11-06 | $12.18M 10-Q · filed 2025-11-06 | $14.62M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$138.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $11.86M 10-Q · filed 2025-08-07 | $14.29M derived: sum of 3 quarters · filed 2025-08-07 | $14.29M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $11.99M 10-Q · filed 2025-05-07 | $14.43M derived: sum of 2 quarters · filed 2025-05-07 | $14.43M derived: sum of 3 quarters · filed 2025-05-07 | $16.52M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $2.44M derived: sum of 2 quarters · filed 2025-03-20 | $4.53M derived: sum of 3 quarters · filed 2025-03-20 | $4.52M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $2.09M derived: sum of 2 quarters · filed 2024-11-13 | $2.08M 10-Q · filed 2024-11-13 | $7.22M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.08M 10-Q · filed 2024-08-08 | $7.23M derived: sum of 3 quarters · filed 2024-08-08 | $8.10M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$10.00K 10-Q · filed 2024-05-07 | $5.13M derived: sum of 2 quarters · filed 2024-05-07 | $6.00M derived: sum of 3 quarters · filed 2024-05-07 | $5.63M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $5.14M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $6.01M derived: sum of 2 quarters · filed 2024-03-26 | $5.64M derived: sum of 3 quarters · filed 2024-03-26 | $5.55M 10-K · filed 2024-03-26 |
| 2022-09-30 | $869.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $495.00K derived: sum of 2 quarters · filed 2023-11-02 | $404.00K 10-Q · filed 2023-11-02 | $46.77M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$374.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$465.00K 10-Q · filed 2023-08-08 | $45.90M derived: sum of 3 quarters · filed 2023-08-08 | $44.94M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$91.00K 10-Q · filed 2023-05-04 | $46.27M derived: sum of 2 quarters · filed 2023-05-04 | $45.31M derived: sum of 3 quarters · filed 2023-05-04 | $44.15M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $46.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $45.40M derived: sum of 2 quarters · filed 2023-03-23 | $44.24M derived: sum of 3 quarters · filed 2023-03-23 | $53.20M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$961.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$2.12M derived: sum of 2 quarters · filed 2022-11-14 | $6.84M 10-Q · filed 2022-11-14 | $7.29M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $7.80M 10-Q · filed 2022-08-09 | $8.25M derived: sum of 3 quarters · filed 2022-08-09 | |
| 2021-03-31 | $8.96M 10-Q · filed 2022-05-11 | $9.40M derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $445.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $5.76M 10-K · filed 2022-03-30 | ||
| 2020-09-30 | $5.32M 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |